about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceRecent Advances in Antiviral Therapy for Chronic Hepatitis CMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsNew treatment strategies for hepatitis C infectionDevelopment of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisionsA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankUltra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants.Novel permissive cell lines for complete propagation of hepatitis C virus.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Small RNA fragments derived from multiple RNA classes - the missing element of multi-omics characteristics of the hepatitis C virus cell culture modelOxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceHepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenanceTreatment of norovirus infections: moving antivirals from the bench to the bedside.Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.New horizons in hepatitis C antiviral therapy with direct-acting antivirals.New treatments for chronic hepatitis C: an overview for paediatricians.Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.Overcoming drug resistance in HSV, CMV, HBV and HCV infection.The role of HCV proteins on treatment outcomes.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Caffeine inhibits hepatitis C virus replication in vitro.Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.Management of direct antiviral agent failures.Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
P2860
Q26740219-F7F4C65A-D6DA-4DE0-874A-9AC51367797EQ26750476-BCA399C7-D8EF-41EF-9B40-D65FC8A12B14Q26773321-C85E106A-525E-44E3-AC32-31DD5055900EQ26777408-B835B387-9D4D-4A2A-B0AC-FF7E2D162A1AQ26795407-82CB2094-B61C-49DC-9B58-4A6DCC8EA3F0Q27468990-0509A058-844A-49EC-92DB-24818509C6AFQ28541048-005DF1A4-E757-4698-AC76-9C9192732F97Q28553430-D9ADAA2D-ED39-465E-82BF-58FC858443C8Q30726364-B3F6ED53-09DF-4AE4-83B7-6AB0E65C102DQ33602824-FE284D61-6E3A-4F16-B139-C8E0C20710A0Q33853664-D835276D-1C6C-4A30-907A-8F6B71966B57Q33861677-DB26BF57-3A4C-43C9-A110-990C40962A14Q33904328-3EAD81F1-A469-4D3A-B092-5E16B28E07F4Q34008754-82CBA0D9-1F07-499D-BB01-8ACC01FF9CC9Q34332546-E5472E24-A060-45D6-8297-B5305919FACEQ34411617-76FC6F8B-DDD7-4559-B076-6A0493632DFDQ34522481-36F6D2A2-5929-49B8-9008-7AFEBBC88AE2Q34599453-1AF84DBB-2737-4262-8AA8-842B8F3A5450Q34983102-4D83687B-3D7B-4232-983D-F57758CF71E9Q35100139-1C7CB50D-951D-4426-B398-CB84F572DE91Q35759025-7891D4E0-7551-4F79-B3FB-4ACF7E60EF73Q36290778-F1D929E5-B40F-479E-9DAC-B44747515571Q36562909-319B6F20-ECEC-4921-95E7-90902C32026CQ36691408-703DCBB5-4E4A-4D3B-B76A-BD9660E97AEEQ36933403-34FC1008-B5FB-427C-94E2-B8595C3517B9Q36988456-C3A3BA1F-1315-4D1A-88DC-6645F0858D79Q37699395-CC3EFC88-B468-4084-81C2-F1C076AD3D6DQ38087250-6FFD27C1-9BC5-447F-91CE-881BD711AA5AQ38282842-D8F17D8D-17E7-43A3-AADA-F46078D94BF7Q38407722-8533D985-A9D3-4A42-A7BD-1C88F45150CCQ38460386-63949A3E-C1E7-4F3D-84F4-3D663E282610Q38622013-BC18F316-2224-44D8-8D5F-675297488FFAQ38668968-BC585ACA-1741-44CA-88F8-B567DB595BB1Q38849307-327583DB-E58A-4154-B250-5AFD811BA7F8Q38930548-A8CB4A58-1D09-4C23-821F-F4B492E843E2Q38945754-8462D3C9-3A68-43B9-8E71-E18A1DBE2B7BQ39020651-E3F2FC77-CD94-478F-899B-D276F09DA089Q39024201-B653780D-FDD4-406A-B028-F66D51943A14Q39182744-7E9F72C9-01E8-424F-BA13-B26774E23A8CQ39824771-166E9BB2-9877-43B2-B21B-2CE4DC3F644B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of resistance in HCV treatment.
@en
type
label
The role of resistance in HCV treatment.
@en
prefLabel
The role of resistance in HCV treatment.
@en
P1476
The role of resistance in HCV treatment.
@en
P2093
Christoph Sarrazin
Johannes Vermehren
P304
P356
10.1016/J.BPG.2012.09.011
P577
2012-08-01T00:00:00Z